Welcome to our dedicated page for NeuroBo Pharmaceuticals news (Ticker: NRBO), a resource for investors and traders seeking the latest updates and insights on NeuroBo Pharmaceuticals stock.
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) is a clinical-stage biotechnology company dedicated to developing and commercializing transformative therapies for cardiometabolic diseases. Headquartered in Boston, Massachusetts, and established in 2017, NeuroBo is at the forefront of innovative solutions aimed at conditions like obesity, metabolic dysfunction-associated steatohepatitis (MASH), and Type 2 Diabetes Mellitus (T2DM).
The company's robust product pipeline includes two primary programs:
- DA-1241: This novel G-Protein-Coupled Receptor 119 (GPR119) agonist aims to treat MASH and T2DM. In preclinical studies, DA-1241 has shown promising results in reducing hepatic steatosis, inflammation, liver fibrosis, and improving glucose control. The Phase 2a clinical trial is currently evaluating its efficacy and safety, with an expected data readout in the second half of 2024.
- DA-1726: A dual oxyntomodulin (OXM) analog functioning as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) agonist, designed to address obesity. Preclinical evidence suggests that DA-1726 offers superior weight loss and a better tolerability profile compared to existing GLP-1 agonists. The Phase 1 clinical trial is underway with an anticipated data readout in the first half of 2025.
In addition to its primary programs, NeuroBo continues to advance its legacy therapeutics, including ANA001 for viral diseases, NB-01 for painful diabetic neuropathy, NB-02 for neurodegenerative diseases, and Gemcabene for dyslipidemia. The company's commitment to leveraging advanced biotechnology aims to meet significant unmet medical needs, providing patients with novel, effective treatments.
Recent achievements include FDA clearance for the IND application of DA-1726 and the initiation of Phase 1 clinical trials. NeuroBo also secured Institutional Review Board (IRB) approval to further expedite their research and development processes.
For more comprehensive information, please visit NeuroBo Pharmaceuticals' official website.
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has submitted an Investigational New Drug (IND) application to the FDA for DA-1241, a GPR119 agonist targeting nonalcoholic steatohepatitis (NASH). This milestone follows the acquisition of DA-1241 and aims to address the unmet needs in NASH treatment. Preclinical results suggest DA-1241 may reduce liver fat and improve glucose metabolism. The Phase 2a trial will include 87-98 subjects, focusing on changes in ALT levels as the primary endpoint. Upcoming key milestones include patient enrollment in Q3 2023 and data expected in H2 2024. NeuroBo also plans to progress DA-1726 through the IND process this year.
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has announced its strategic focus on cardiometabolic diseases following the acquisition of promising assets targeting nonalcoholic steatohepatitis (NASH), obesity, and type 2 diabetes. The company completed a public offering of $17.3 million and received a $15 million private investment from Dong-A, becoming its largest shareholder. For 2022, R&D expenses decreased to $2.8 million, while net loss narrowed to $14.0 million, or $5.43 per share. Cash and equivalents rose to $33.4 million, expected to support operations into 2024, including upcoming clinical trials for DA-1241 and DA-1726.
NeuroBo Pharmaceuticals, a clinical-stage biotechnology company (Nasdaq: NRBO), has appointed Joseph Hooker as Interim CEO and President following the retirement of Gil Price. Hooker, who brings approximately 40 years of industry experience, will lead the company during its search for a permanent CEO. The Board expressed confidence in Hooker's ability to advance NeuroBo's newly acquired assets, DA-1241 and DA-1726, into clinical development, particularly targeting nonalcoholic steatohepatitis (NASH) and obesity. In November 2022, NeuroBo secured $32.3 million in financing to bolster its financial position and support ongoing operations.
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has closed a public offering generating $17.3 million and a concurrent private placement raising $15 million. The public offering included 3,147,003 Class A Units and 2,602,997 Class B Units, priced at $3.00 each. NeuroBo also secured an exclusive license from Dong-A ST Co., Ltd. for DA-1241 and DA-1726, aimed at treating NASH, obesity, and type 2 diabetes. The license includes an upfront payment of $22 million worth of Series A Convertible Preferred Stock. Stockholder meetings are anticipated by December 22, 2022.
NeuroBo Pharmaceuticals (NASDAQ: NRBO) announced a $30 million underwritten public offering and concurrent private placement, with units priced at $3.00 each. The offering includes 2,397,003 Class A Units and 2,602,997 Class B Units, each comprising shares of common stock and warrants. A total of 10 million warrants will accompany the offering. Additionally, NeuroBo plans to sell $15 million in convertible preferred stock and warrants to Dong-A St. Co. Ltd. The closing date is projected for November 8, 2022.
FAQ
What is the current stock price of NeuroBo Pharmaceuticals (NRBO)?
What is the market cap of NeuroBo Pharmaceuticals (NRBO)?
What is NeuroBo Pharmaceuticals, Inc.?
What are NeuroBo's primary programs?
What is DA-1241?
What is DA-1726?
Where is NeuroBo Pharmaceuticals headquartered?
When was NeuroBo Pharmaceuticals founded?
What recent initiatives has NeuroBo announced?
What are NeuroBo's legacy therapeutics?
How can I learn more about NeuroBo Pharmaceuticals?
What is the significance of DA-1726?
